Jennison Associates LLC Has $49.59 Million Holdings in Solventum Corporation $SOLV

Jennison Associates LLC lifted its holdings in shares of Solventum Corporation (NYSE:SOLV) by 12.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 625,764 shares of the company’s stock after acquiring an additional 67,227 shares during the period. Jennison Associates LLC’s holdings in Solventum were worth $49,586,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. United Services Automobile Association acquired a new position in Solventum in the first quarter valued at approximately $239,000. Woodline Partners LP grew its holdings in Solventum by 40.7% during the 1st quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock worth $888,000 after acquiring an additional 3,377 shares during the period. Intech Investment Management LLC grew its holdings in Solventum by 167.0% during the 1st quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock worth $1,268,000 after acquiring an additional 10,425 shares during the period. First Trust Advisors LP raised its position in shares of Solventum by 5.8% during the 2nd quarter. First Trust Advisors LP now owns 257,727 shares of the company’s stock valued at $19,546,000 after acquiring an additional 14,151 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Solventum during the 2nd quarter valued at $766,000.

Analysts Set New Price Targets

SOLV has been the topic of several recent research reports. Wells Fargo & Company upgraded Solventum to a “hold” rating in a research report on Wednesday, March 18th. Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Piper Sandler cut their target price on Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Stifel Nicolaus raised their target price on Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Finally, Mizuho set a $100.00 target price on Solventum and gave the stock an “outperform” rating in a research report on Tuesday, January 20th. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Solventum has a consensus rating of “Hold” and an average target price of $89.45.

Insider Activity

In other Solventum news, Director Amy Mcbride Wendell acquired 1,475 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The stock was acquired at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the transaction, the director owned 5,039 shares of the company’s stock, valued at $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.24% of the company’s stock.

Solventum Stock Performance

Shares of Solventum stock opened at $67.44 on Friday. The stock’s fifty day simple moving average is $67.99 and its 200 day simple moving average is $74.48. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00. The company has a market capitalization of $11.69 billion, a PE ratio of 7.60, a PEG ratio of 1.09 and a beta of 0.71. Solventum Corporation has a 12 month low of $62.38 and a 12 month high of $88.20.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $1.96 billion. During the same period in the previous year, the firm earned $1.41 earnings per share. The company’s revenue was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. On average, research analysts predict that Solventum Corporation will post 6.5 EPS for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.